Literature DB >> 16000360

When and how to treat essential thrombocythemia.

Tiziano Barbui, Guido Finazzi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16000360     DOI： 10.1056/NEJMe058093

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  12 in total

Review 1.  Anagrelide: a review of its use in the management of essential thrombocythaemia.

Authors:  Antona J Wagstaff; Gillian M Keating
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?

Authors:  Tiziano Barbui; Alessandra Carobbio; Alessandro Rambaldi; Guido Finazzi
Journal:  Blood       Date:  2009-04-16       Impact factor: 22.113

3.  Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia.

Authors:  Alessandra Carobbio; Guido Finazzi; Elisabetta Antonioli; Paola Guglielmelli; Alessandro M Vannucchi; Federica Delaini; Vittoria Guerini; Marco Ruggeri; Francesco Rodeghiero; Alessandro Rambaldi; Tiziano Barbui
Journal:  Blood       Date:  2008-06-27       Impact factor: 22.113

Review 4.  Polycythaemia vera and essential thrombocythaemia: current treatment strategies.

Authors:  Elisabeth I Penninga; Ole W Bjerrum
Journal:  Drugs       Date:  2006       Impact factor: 9.546

5.  Essential thrombocythemia in a young man treated for myocardial infarction.

Authors:  S Pande; R Joshi; R Pande
Journal:  BMJ Case Rep       Date:  2010-08-03

Review 6.  Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2V617F mutations and laboratory findings: a meta-analysis.

Authors:  N Saki; R Shirzad; F Rahim; A Saki Malehi
Journal:  Clin Transl Oncol       Date:  2017-02-15       Impact factor: 3.405

7.  Subcellular mislocalization of the transcription factor NF-E2 in erythroid cells discriminates prefibrotic primary myelofibrosis from essential thrombocythemia.

Authors:  Konrad Aumann; Anna-Verena Frey; Annette M May; Dieter Hauschke; Clemens Kreutz; Jan P Marx; Jens Timmer; Martin Werner; Heike L Pahl
Journal:  Blood       Date:  2013-05-13       Impact factor: 22.113

8.  [Differential diagnosis of myeloproliferative neoplasms. Quantitative NF-E2 immunohistochemistry for differentiating between essential thrombocythemia and primary myelofibrosis].

Authors:  K Aumann; A-V Frey; A M May; D Hauschke; C Kreutz; J P Marx; J Timmer; M Werner; H L Pahl
Journal:  Pathologe       Date:  2013-11       Impact factor: 1.011

9.  Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term results.

Authors:  Roberto Latagliata; Angela Rago; Antonio Spadea; Cristina Santoro; Ida Carmosino; Massimo Breccia; Laura Napoleone; Angelo Fama; Francesca Biondo; Paola Volpicelli; Federico Vozella; Caterina Stefanizzi; Maria Concetta Petti; Giuliana Alimena; Maria Gabriella Mazzucconi
Journal:  Int J Hematol       Date:  2009-08-22       Impact factor: 2.490

10.  Postpartal recurrent non-ST elevation myocardial infarction in essential thrombocythaemia: case report and review of the literature.

Authors:  Spyridon Arampatzis; Ioannis Stefanidis; Vassilios Lakiopoulos; Luigi Raio; Daniel Surbek; Markus G Mohaupt
Journal:  Thromb J       Date:  2010-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.